✦ LIBER ✦

Ocular Defects as Surrogate End-Points in Trials Comparing Carotid Endarterectomy and Stenting

✍ Scribed by Giannoukas, A.D.; Paraskevas, K.I.; Bulbulia, R.; Halliday, A.

Book ID: 122299158
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 92 KB
Volume: 48
Category: Article
ISSN: 1078-5884
DOI: 10.1016/j.ejvs.2014.03.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Surrogates, substudies, and real clinica

Surrogates, substudies, and real clinical end points in trials of drug-eluting stents

✍ Dean J. Kereiakes; Richard E. Kuntz; Laura Mauri; Mitchell W. Krucoff 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Quantitative liver function tests as sur

Quantitative liver function tests as surrogate markers for end-points in controlled clinical trials: A retrospective feasibility study

✍ E Lotterer; J Hogel; W Gaus; W E Fleig; J Bircher 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB

and nonabstinent patients with alcoholic liver disease investigated in this study, such numbers could serve for the planning Quantitative liver function tests such as the determination of controlled clinical trials, in which the control group is likely to deteriorate and the treated group is expecte

Quantitative liver function tests as sur

Quantitative liver function tests as surrogate markers for end-points in controlled clinical trials: A retrospective feasibility study

✍ E Lotterer; J Hogel; W Gaus; WE Fleig; J Bircher 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB

Estimated GFR Decline as a Surrogate End

Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)

✍ Lambers Heerspink, Hiddo J.; Weldegiorgis, Misghina; Inker, Lesley A.; Gansevoor 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 630 KB